Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spesolimab - Boehringer Ingelheim

Drug Profile

Spesolimab - Boehringer Ingelheim

Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGO

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Generalised pustular psoriasis
  • Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
  • Phase II Crohn's disease; Palmoplantar pustulosis; Pyoderma gangrenosum
  • Discontinued Atopic dermatitis

Most Recent Events

  • 26 Apr 2024 Boehringer Ingelheim completes phase-II clinical trials in Hidradenitis suppurativa in Poland, Greece, USA, Canada, France, Hungary, Australia, Belgium, Czech Republic, Germany, Italy, Netherlands, Norway, Spain, Denmark. Italy, UK (SC) (IV) (NCT04876391)
  • 16 Apr 2024 Phase-II/III clinical trials in Hidradenitis suppurativa (Treatment-experienced) in Canada (SC) (NCT06241573) (EudraCT2023-508377-82-00)
  • 19 Mar 2024 Launched for Generalised pustular psoriasis (In adolescents, In children) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top